References
- Bai S. A., Wilson M. J., Walle U. K., Walle T. Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. Journal of Pharmacology and Experimental Therapeutics 1993; 227: 360–364
- Bastian G., Urien S., Bree F., Jolliet P., Rocher I., Crambes O., Tillement J. P. Stereoselective binding of tertatolol and of 4-hydroxytertatolol to human plasma proteins. European Journal of Drug Metabolism and Pharmacokinetics 1992; 17: 2–4
- Campbell D. B., Chignon J. C., Devissaguet J. Ph. Biodisposition of tertatolol in man. American Journal of Nephrology 1986; 6: 61–68
- Degaute J. P., Naieje R., Abramovicz M., Leeman M., Schoutens A., Prost J. F. Acute effects of tertatolol and nadolol on systemic and renal hemodynamics in patients with essential hypertension. American Journal of Hypertension 1988; 1: 2635–2685
- Efthymiopoulos C., Staveris S., Weber F., Koffel J. C., Jung L. Simultaneous quantitative determination of tertatolol and its hydroxylated metabolite in human plasma and urine by gas chromatography-mass spectrometry. Journal of Chromatography 1987; 421: 360–366
- Laubie M., Schmitt H., Mouille P., Cheymol G., Gilbert J. C. Effets Adrénolytiques Běta et Hémodynamiques du dl (Hydroxy 2′ t-Butylamino 3′ Propyloxy) 8-Thiochromane (S2395). Archives Internationales de Pharmacodynamie 1973; 201: 334–346
- Lave T., Efthymiopoulos C., Sanwald P., Koffel J. C., Jung L. Stereoselectivity of plasma and tissue distribution of tertatolol enantiomers in rat. International Journal of Clinical Pharmacology Therapeutics and Toxicology 1992; 30: 301
- Salvetti A., Leonetti G., Bernini G. P. Antihypertensive and renal effects of tertatolol, a new beta-blocking agent in hypertensive patients. American Journal of Nephrology 1986; 6: 45–49
- Smits J. F. M., Zeegers H. H., Struyker-Boudier H. A. J. Stereospecificity of beta-adrenoreceptor blockade and renal vasodilatation by tertatolol. Archives Internationales de Pharmacodynamie 1989; 298: 164–171
- Stephan D., Barthelmebs M., Krieger J. P., Decker N., Rochat C., Imbs J. L. Effect of tertatolol and of its metabolites and structural analogues in isolated perfused rat kidney vasculature. Journal of Cardiovascular Pharmacology, 16: 338–346
- Takahashi T., Ogata H., Kanno S., Takeuchi H. Plasma protein binding of propranolol enantiomers as a major determinant of their stereoselective tissue distribution in rats. Journal of Pharmacology and Experimental Therapeutics 1990; 252: 272–278
- Urien S., Morin D., Renouard A., Rocher I., Tillement J. P. Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration. European Journal of Clinical Pharmacology 1988; 34: 381–385
- Walle T., Webb J. G., Bagwell E. E., Walle U. K., Daniell H. B., Gaffney T. E. Stereoselective delivery and actions of beta receptor antagonists. Biochemical Pharmacology 1988; 37: 115–124
- Wilson B. K., Thompson J. A. Glucuronidation of propranolol by dog liver microsomes; effects of enantiomeric inhibition and detergent treatment on stereoselectivity. Drug Metabolism and Disposition 1984; 12: 161–164
- Yuan J. Estimation of variance for AUC in animal studies. Journal of Pharmaceutical Sciences 1993; 82: 761–763